title: Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
abstract: Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prevention of relapse to opioid dependence, after opioid detoxification. The clinical efficacy of this formulation in patients with opioid dependence was demonstrated in a 24-week, randomized, double-blind, placebo-controlled, multicentre, phase III trial (ALK21-013; n = 250). In this trial, opioid-detoxified patients receiving XR-NTX 380 mg once every 4 weeks, in combination with psychosocial support, had a significantly higher median proportion of weeks of confirmed opioid abstinence during weeks 5-24, compared with those receiving placebo (primary endpoint). A significantly higher proportion of patients receiving XR-NTX achieved total confirmed abstinence during this period than those receiving placebo. XR-NTX was also associated with a significantly greater reduction in opioid craving and a significantly longer treatment retention period than placebo. XR-NTX was generally well tolerated in the phase III trial. The most common (incidence ≥5 %) treatment-emergent adverse events that also occurred more frequently with XR-NTX than with placebo were hepatic enzyme abnormalities, nasopharyngitis, insomnia, hypertension, influenza and injection-site pain. Thus, XR-NTX is a useful treatment option for the prevention of relapse to opioid dependence, following opioid detoxification.
authors.affiliation: Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand, demail@springer.com.
authors.forename: Yahiya Y
authors.initials: YY
authors.lastname: Syed
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Keating
mesh_terms: D000328:Adult; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D006801:Humans; D007273:Injections, Intramuscular; D009271:Naltrexone / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy / Q000517:prevention & control*; D055502:Secondary Prevention
chemical_list: D003692:Delayed-Action Preparations; D009292:Narcotic Antagonists; D009271:Naltrexone
references.citation: Addiction. 2013 Sep;108(9):1628-37
references.pmid: 23701526
references.citation: Am J Manag Care. 2011 Jun;17 Suppl 8:S235-48
references.pmid: 21761950
references.citation: Drugs. 1988 Mar;35(3):192-213
references.pmid: 2836152
references.citation: Drugs. 2012 Jan 22;72(2):217-28
references.pmid: 22235870
references.citation: Alcohol Clin Exp Res. 2006 Mar;30(3):480-90
references.pmid: 16499489
references.citation: IDrugs. 2002 Aug;5(8):835-8
references.pmid: 12802700
references.citation: Addiction. 2010 Sep;105(9):1669-76
references.pmid: 20626723
references.citation: Arch Gen Psychiatry. 2006 Feb;63(2):210-8
references.pmid: 16461865
references.citation: J Stud Alcohol Drugs. 2007 Nov;68(6):862-70
references.pmid: 17960304
references.citation: Neuropsychopharmacology. 2003 Nov;28(11):1973-82
references.pmid: 12931140
references.citation: J Stud Alcohol Drugs. 2012 Nov;73(6):991-7
references.pmid: 23036218
references.citation: Lancet. 2011 Apr 30;377(9776):1506-13
references.pmid: 21529928
references.citation: J Clin Pharmacol. 2005 Nov;45(11):1259-67
references.pmid: 16239359
references.citation: Lancet. 2010 Mar 20;375(9719):1014-28
references.pmid: 20189638
references.citation: Pain Med. 2011 Apr;12(4):657-67
references.pmid: 21392250
references.citation: Drug Alcohol Depend. 2012 Jun 1;123(1-3):57-65
references.pmid: 22079773
references.citation: JAMA. 2005 Mar 23;293(12):1513-5
references.pmid: 15784877
references.citation: Drugs. 2006;66(13):1741-51
references.pmid: 16978037